Hua Medicine represents strong values and a strategic corporate philosophy. The company is dedicated to improving the lives of patients with innovative medicines, particularly in the field of diabetes and metabolic disorders. They strive for scientific excellence, putting a strong emphasis on research and development, and forging strategic partnerships to enhance their drug discovery and development capabilities. Hua Medicine is committed to providing solutions that address the unmet medical needs of patients, while upholding the highest ethical standards. With a focus on advancing innovative therapies, Hua Medicine aims to become a leading player in the pharmaceutical industry, delivering lasting value for patients, healthcare professionals, and investors.

Hua Medicine is primarily present in several countries and regions. These include China, where the company is headquartered, as well as other Asian countries such as Japan and South Korea. Hua Medicine also has a presence in the United States, where it conducts research and development activities. Furthermore, the company is expanding its reach into European markets by collaborating with various partners. With a global presence, Hua Medicine aims to bring its innovative treatments and therapies to patients worldwide.

Hua Medicine has achieved several significant milestones in its journey. Notably, the company successfully completed a Phase 2b clinical trial for its lead drug candidate, dorzagliatin (HMM0301), which demonstrated promising results in treating Type 2 diabetes. Hua Medicine then advanced dorzagliatin to Phase 3 development, aiming for global regulatory approval. The company also secured partnerships with international pharmaceutical companies to promote the commercialization of dorzagliatin. Furthermore, Hua Medicine received multiple research grants and awards for its innovative work in exploring novel treatment options for diabetes. These milestones highlight the company's dedication and progress in revolutionizing diabetes care.

Hua Medicine is a pharmaceutical company based in Shanghai, China. Founded in 2011, it focuses on developing innovative therapies and treatments for diabetes and related metabolic disorders. The company's primary goal is to bridge the gap between Western and Chinese medicine, aiming to provide effective and accessible treatments for patients suffering from these conditions. Hua Medicine has a strong research and development portfolio, and its lead drug candidate, dorzagliatin, has shown promising results in treating type 2 diabetes. With a dedicated team of scientists and researchers, Hua Medicine is committed to improving the lives of individuals affected by diabetes through its groundbreaking therapies.

The main competitors of Hua Medicine in the market include key players in the pharmaceutical industry such as XOMA Corporation, Pfizer Inc., and Novo Nordisk A/S. These companies operate in the same therapeutic area and offer competing products within the diabetes and metabolic disorders space. Hua Medicine's innovative approach and commitment to developing novel treatments set it apart in this competitive market.

Hua Medicine is primarily active in the pharmaceutical industry.

Hua Medicine's business model focuses on developing innovative therapies to address significant unmet medical needs. The company primarily focuses on the research and development of drugs for the treatment of diabetes and other metabolic diseases. Hua Medicine utilizes a research-driven approach and strives to identify novel drug targets and develop effective solutions. With a strong emphasis on scientific expertise and collaborations with global partners, Hua Medicine aims to bring breakthrough treatments to patients worldwide. By leveraging its deep understanding of pathways and disease mechanisms, Hua Medicine is committed to transforming the treatment landscape and improving the lives of individuals affected by metabolic disorders.

Hua Medicine KGV yra −2,58.

Hua Medicine KUV yra 2,04.

AlleAktien kokybės įvertis Hua Medicine yra 1/10.

tikėtina Hua Medicine pardavimai yra 549,78 mln. CNY.

tikėtina Hua Medicine pelnas yra −435,06 mln. CNY.

Hua Medicine is a biopharmaceutical company specializing in the research and development of innovative therapeutics for the treatment of diabetes and other metabolic disorders. The company aims to help patients worldwide by focusing on the discovery and development of novel compounds that are highly effective and safe. One of Hua Medicine's key strategies is understanding diabetes as a disease caused not by a single factor, but by a combination of factors. To effectively treat and cure this complex condition, the company has established an extensive research and development program focused on identifying molecules that target multiple therapeutic goals in the body. Hua Medicine has a wide range of product candidates in development, including Novel Oral Antidiabetic Agents (NOAA) such as HMS5552, a new pharmacological class targeting the treatment of type 2 diabetes. HMS5542 is a unique compound that has shown promising safety and efficacy data in clinical studies. The drug is currently in late-stage clinical development and is expected to be launched on the market in the near future. HMS5552 works by blocking an enzyme called DPP-4, which has various effects in the body, including glucose control. It can also increase insulin production in the body and slow down the breakdown of glucose from food. Additionally, the drug has the potential to offer long-term benefits to patients by potentially slowing down the progression of insulin resistance and beta-cell dysfunction, the two key factors influencing the course of type 2 diabetes. In addition to NOAA products, Hua Medicine is also working on the development of nucleic acid-based therapeutics and peptide-based therapeutics for diabetes and other metabolic disorders. The company has a strong research and development pipeline and is committed to continuous innovation in the field of diabetes therapy. Hua Medicine follows an integrated value creation strategy that includes research and development, manufacturing and marketing of products, as well as partnerships with other companies. The company aims to expand its product portfolio through strategic collaborations and alliances with other companies and organizations to support the rapid and efficient commercialization of its products. In summary, Hua Medicine is a leading biopharmaceutical company focused on the development of therapeutics for diabetes and other metabolic disorders. The company has a strong research and development pipeline and an integrated value creation strategy aimed at rapid and efficient commercialization of its products. With its strong commitment to innovation and excellence, Hua Medicine is well positioned to change the global diabetes therapy landscape and help patients achieve better health and quality of life.

Hua Medicine moka dividendą 0 CNY, kuris yra paskirstytas per išmokas per metus.

Dividenda šiuo metu negali būti apskaičiuota Hua Medicine arba įmonė dividendų nemoka.

Hua Medicine ISIN yra KYG4644K1022.

Hua Medicine akcijų simbolis yra 2552.HK.

Per paskutinius 12 mėnesių Hua Medicine išmokėjo dividendą, kurios dydis siekė . Tai atitinka maždaug dividendų grąžą. Artimiausiems 12 mėnesiams Hua Medicine tikėtina išmokės dividendus, kurie sudarys 0 CNY.

Hua Medicine šiuo metu yra dydžio dividendų grąža.

Hua Medicine moka dividendus kas ketvirtį. Jie išmokami mėnesiais.

Hua Medicine per paskutiniuosius 0 metus kiekvienais metais mokėjo dividendus.

Artimiausiems 12 mėnesiams tikimasi dividendų, kurių dydis yra 0 CNY. Tai atitinka 0 % dividendų grąžos procentą.

Hua Medicine priskiriamas sektoriui "Sveikata".

Norėdamas gauti paskutinį Hua Medicine dividendą nuo 2024-08-01, kurio dydis yra 0 CNY, turėjai turėti akciją savo depozite prieš ex-dieną, kuri buvo 2024-08-01.

Paskutinės dividendų išmokėjimas įvyko 2024-08-01.

2023 metais Hua Medicine išmokėjo 0 CNY dividendų.

Hua Medicine dividendai yra mokami CNY.